Halozyme Therapeutics Stock Analysis (NASDAQ:HALO)

Add to My Stocks
$13.53 $0.07 (0.52%) HALO stock closing price Jul 26, 2017 (Closing)
Watch Robo Advisor Video of HALO Stock Analysis
Halozyme Therapeutics
Updated on : Jul 26, 2017
previous close
HALO 13.5 (0%)
S&P 500 2477.8 (0%)
Closing Price On: Jul 26, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
19%
Operating Profit
Operating Margin:
-70.7%
Sector Average:
-0.5%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Cash Flow
Operating cash flow:
-$22.5M
Net Income:
-$32.9M
PROS      CONS
Long Term Growth
Operating Margins
Net Margins
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
HALO PS :
13
Industry PS :
5.2
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Free Cash Flow Margin:
-76.2%
Double Tap To Exit Full Screen
0:00
/

Halozyme Therapeutics Analysis Video

125 5 2

View Halozyme Therapeutics stock analysis video. This is our HALO analyst opinion covering the buy and sell arguments for HALO stock.

Halozyme Therapeutics, Inc. Stock Rating (2/5)

Our Halozyme Therapeutics stock opinion is based on fundamentals of the company. This Halozyme Therapeutics stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy HALO stock?

  • Revenue growth has been tremendous with a compounded annual growth of 19% over the last 5 years.

Should you sell HALO stock?

  • Halozyme Therapeutics registered a negative operating margin of -70.7% (average) over the Trailing Twelve Months (TTM).
  • Halozyme Therapeutics posted an average Net loss of -86.8% in the last twelve months.
  • PE ratio is meaningless for HALO stock as the company has losses.
  • The company is trading at a price to sales multiple of 13, which is overvalued in comparison to the Medical-Biomed-Genetics industry average multiple of 5.2.
  • Halozyme Therapeutics has a negative FCF (Free Cash Flow) margin of -76.2%.

Comments on this video and Halozyme Therapeutics stock